Abbott's Xience V approved in Japan
This article was originally published in The Gray Sheet
Firm's Xience V everolimus-eluting coronary stent and a version of the device marketed by Boston Scientific as Promus will debut in Japan in the "coming weeks," pending final reimbursement authorization, now that marketing approval has been received from Japan's Ministry of Health, Labor and Welfare, the companies announced Jan. 8. Japan is the second largest stent market after the U.S., where the device debuted in 2008
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.